Mass spectrometric analysis of the in vitro secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation on response to interleukin-1β treatment by Bundgaard, Louise et al.
 
  
 
Aalborg Universitet
Mass spectrometric analysis of the in vitro secretome from equine bone marrow-
derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation
on response to interleukin-1 treatment
Bundgaard, Louise; Stensballe, Allan; Elbæk, Kirstine Juul; Berg, Lise Charlotte
Published in:
Stem Cell Research & Therapy
DOI (link to publication from Publisher):
10.1186/s13287-020-01706-7
Creative Commons License
CC BY 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Bundgaard, L., Stensballe, A., Elbæk, K. J., & Berg, L. C. (2020). Mass spectrometric analysis of the in vitro
secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic
differentiation on response to interleukin-1 treatment. Stem Cell Research & Therapy, 11(1), [187].
https://doi.org/10.1186/s13287-020-01706-7
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
RESEARCH Open Access
Mass spectrometric analysis of the in vitro
secretome from equine bone marrow-
derived mesenchymal stromal cells to
assess the effect of chondrogenic
differentiation on response to interleukin-
1β treatment
Louise Bundgaard1* , Allan Stensballe2, Kirstine Juul Elbæk2 and Lise Charlotte Berg1
Abstract
Background: Similar to humans, the horse is a long-lived, athletic species. The use of mesenchymal stromal cells
(MSCs) is a relatively new frontier, but has been used with promising results in treating joint diseases, e.g., osteoarthritis.
It is believed that MSCs exert their main therapeutic effects through secreted trophic biomolecules. Therefore, it has
been increasingly important to characterize the MSC secretome. It has been shown that the effect of the MSCs is
strongly influenced by the environment in the host compartment, and it is a crucial issue when considering MSC
therapy. The aim of this study was to investigate differences in the in vitro secreted protein profile between naïve and
chondrogenic differentiating bone marrow-derived (BM)-MSCs when exposed to an inflammatory environment.
Methods: Equine BM-MSCs were divided into a naïve group and a chondrogenic group. Cells were treated with
normal expansion media or chondrogenic media. Cells were treated with IL-1β for a period of 5 days (stimulation),
followed by 5 days without IL-1β (recovery). Media were collected after 48 h and 10 days. The secretomes were
digested and analyzed by nanoLC-MS/MS to unravel the orchestration of proteins.
Results: The inflammatory proteins IL6, CXCL1, CXCL6, CCL7, SEMA7A, SAA, and haptoglobin were identified in the
secretome after 48 h from all cells stimulated with IL-1β. CXCL8, OSM, TGF-β1, the angiogenic proteins VCAM1, ICAM1,
VEGFA, and VEGFC, the proteases MMP1 and MMP3, and the protease inhibitor TIMP3 were among the proteins only
identified in the secretome after 48 h from cells cultured in normal expansion media. After 10-day incubation, the proteins
CXCL1, CXCL6, and CCL7 were still identified in the secretome from BM-MSCs stimulated with IL-1β, but the essential
inducer of inflammation, IL6, was only identified in the secretome from cells cultured in normal expansion media.
(Continued on next page)
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Conclusion: The findings in this study indicate that naïve BM-MSCs have a more extensive inflammatory response at 48 h
to stimulation with IL-1β compared to BM-MSCs undergoing chondrogenic differentiation. This extensive inflammatory
response decreased after 5 days without IL-1β (day 10), but a difference in composition of the secretome between naïve
and chondrogenic BM-MSCs was still evident.
Keywords: Mesenchymal stromal cells, Equine, Mass spectrometry, Secretome, Inflammation, Chondrogenic differentiation,
Joint disease
Background
Similar to humans, the horse is a long-lived, athletic
species. Osteoarthritis (OA) including joint inflamma-
tion and cartilage degradation is one of the leading
causes of lameness in horses, but there is still no cure
to prevent the progressive degradation of the joint tis-
sue or restore normal joint anatomy. Therefore, the
goals for the treatments used for decades have been
to slow the progression of the disease, minimize pain,
and increase the function of the joint [1]. The use of
mesenchymal stromal cells (MSCs) in treating joint
diseases is a relatively new frontier, but has been used
with promising results in the clinic [2, 3], and cell-
based therapies are seen as the next-generation treat-
ment of joint diseases.
It was originally proposed that transdifferentiation or
cell fusion of transplanted MSCs was the principal
mechanism underlying their therapeutic action in tissue
regeneration [4]. But it is now believed that MSCs exert
their main therapeutic effects through secreted trophic
biomolecules acting in a paracrine fashion [5]. There-
fore, it has been increasingly important to characterize
the MSC secretome, and omics approaches have proved
very useful for this purpose [6–9]. Indeed, identification
of key MSC-secreted factors might be central in the de-
sign of next-generation joint disease therapeutics. The
array of mechanisms affected by the MSC secretome
spans from cell division and cell survival [10] to angio-
genesis [11], extracellular matrix (ECM) organization
[12], immunomodulation [13], and inflammatory re-
sponse [14]. Previous studies have shown that the mode
of MSC action is affected by the environment. A study
of the secretome from human bone marrow (BM)-de-
rived MSCs stimulated with IL-1β identified a broad
spectrum of proteins involved in inflammation and
angiogenesis which were overrepresented in the stimu-
lated MSC secretome [9, 15], and another study of
human osteoarthritic BM-MSCs undergoing chondro-
genic differentiation reported a panel of extracellular
markers potentially useful for cartilage repair after tissue
engineering-based treatments [8]. These findings indicate
that the effect of MSCs will be strongly influenced by the
environment of the host compartment, and it is a crucial
matter when considering MSC therapy.
The aim of this study was to investigate differences in
the in vitro secreted proteome between naïve and chon-
drogenic differentiating BM-derived MSCs when ex-
posed to an inflammatory (IL-1β) environment.
Methods
Study design
Mesenchymal stromal cells derived from the bone mar-
row were divided into a naïve group and a chondrogenic
group. Cells were treated with normal expansion media
or chondrogenic media. Cells were treated with IL-1β
for a period of 5 days (stimulation), followed by 5 days
without IL-1β (recovery). Media were collected after 48 h
and 10 days (Fig. 1).
Isolation and expansion of mesenchymal stromal cells
BM-MSCs were obtained from a 15-year-old standard
bred trotter mare. The horse was euthanized with cap-
tive bolt and exsanguination at the Large Animal Teach-
ing Hospital, University of Copenhagen, for unrelated
reasons.
The MSCs were isolated according to the procedure
described in Bundgaard et al. [16]. In short, BM-MSCs
were isolated from BM aspirated from the sternum,
which together with tuber coxae is the most common
location for bone marrow aspiration in the horse [17].
BM was aspirated using a Jamshidi biopsy needle (11
gauge, 12.7 cm) (Stryker, Kalamazoo, MI, USA) in a 20-
mL syringe preloaded with 1 mL 10% 0.109M trisodium
citrate. The sample was further processed within ~ 1 h
after sampling.
The mononuclear cell fraction was recovered after
Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA)
separation, washed in sterile PBS, and resuspended in
growth medium (GM) (Dulbecco’s modified Eagle’s
medium (DMEM) 1 g/L glucose, with phenol red,
GlutaMAX, and pyruvate (Thermo Fischer Scientific,
Waltham, MA, USA) supplemented with 10% (v/v)
fetal bovine serum (FBS) (Thermo Fischer Scientific,
Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL
streptomycin (Thermo Fischer Scientific, Waltham, MA,
USA), and 25 μg/mL amphotericin B (Thermo Fischer Sci-
entific, Waltham, MA, USA)). The cells were distributed
equally in two T75 cm2 culture flasks and cultured at
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37 °C in a humidified atmosphere containing 5% CO2.
After overnight incubation, non-adherent cells were re-
moved and fresh medium added. Medium was changed
every 2–3 days. Cells were passaged at ~ 80% confluency
(10–12 days) using trypsin-EDTA (0.25%) (Thermo
Fischer Scientific, Waltham, MA, USA). P1 cells were fur-
ther expanded in GM without amphotericin B. At 80%
confluency (8–10 days), cells were detached with trypsin-
EDTA, rinsed in sterile PBS, counted, and cryopreserved
in FBS supplemented with 10% dimethyl sulfoxide
(Sigma-Aldrich, St. Louis, MO, USA) in ~ 2 × 106 aliquots.
Cryopreserved MSCs (~ 2 × 106 cells) were thawed and
expanded in T75 cm2 flasks in GM without amphotericin
B. At ~ 90% confluency (10–12 days), the cells were
passaged as described and replated. When P4 cells
reached ~ 90% confluency (5–6 days), they were harvested
and validated for mesodermal differentiation capacity
using protocols for osteogenesis and chondrogenesis.
Interleukin-1β stimulation and chondrogenic differentiation
Cells (P5) were seeded in 6-well plates at a density of
50,000 cells/well (5208 cells/cm2) and expanded in
GM without amphotericin B. Upon reaching ~ 80%
confluency, wells were washed with sterile PBS and
divided into four treatment groups (6 wells/group).
The treatment groups include expansion media with-
out IL-1β (EM), expansion media with IL-1β (EMIL)
for 5 days followed by 5-day recovery time, chondro-
genic media without IL-1β (CM), or chondrogenic
media with IL-1β (CMIL) for 5 days followed by 5-day re-
covery time. All media were without phenol red, and to
avoid interference from serum proteins in the results, FBS
was substituted with insulin-transferrin-selenium (ITS)
which has proven useful to sustain proliferation and differ-
entiation in several cell types [18, 19]. EM consisted of
DMEM 1 g/L glucose, supplemented with 1% (v/v) Gluta-
MAX (Thermo Fischer Scientific, Waltham, MA, USA), 1%
(v/v) ITS (Thermo Fischer Scientific, Waltham, MA, USA),
and 100U/mL penicillin and 100 μg/mL streptomycin
(Thermo Fischer Scientific, Waltham, MA, USA). CM con-
sisted of DMEM 4.5 g/L glucose, supplemented with 1% (v/
v) GlutaMAX (Thermo Fischer Scientific, Waltham, MA,
USA), 1% (v/v) pyruvate, 1% (v/v) ITS, 100U/mL penicillin
and 100 μg/mL streptomycin, 10−7M dexamethasone
(Sigma-Aldrich, St. Louis, MO, USA), 50 μg/mL ascorbic
acid (L-ascorbic acid 2-phosphate) (Sigma-Aldrich, St.
Louis, MO, USA), and 10 ng/mL TGF-β3 (recombinant
human TGF-β3) (R&D Systems, Inc., Minneapolis, MN,
USA)). EMIL and CMIL were supplemented with IL-1β
(1 μL/mL) (recombinant equine IL-1β) (R&D Systems, Inc.,
Minneapolis, MN, USA). A volume of 1-mL medium was
added per well. After 48 h, media were harvested and
pooled from each treatment group, centrifuged at 2000g for
2min, snap frozen in liquid nitrogen, and stored at − 80 °C
until further processing. Fresh treatment medium was
added to each well including IL-1β for EMIL and CMIL.
Medium was changed on days 5 and 8 to EM and CM
without IL-1β for all wells. All media were harvested on
Fig. 1 Schematic drawing of the workflow. a Bone marrow-derived mesenchymal stromal cells (BM-MSCs) were isolated from the equine sternal
bone marrow. b BM-MSCs were expanded to P4. c The BM-MSCs were seeded in 6-well plates and divided in the following treatment groups: (1)
expansion media without IL-1β (EM), (2) expansion media with IL-1β (EMIL) for 5 days followed by 5 days recovery time, (3) chondrogenic media
without IL-1β (CM), and (4) chondrogenic media with IL-1β (CMIL) for 5 days followed by 5-day recovery time. Media in the 6 wells were
harvested and pooled from each of the treatment groups after 48 h and 10 days. d Samples were concentrated in spin filters, processed,
analyzed by mass spectrometry (MS), and the acquired data interpreted
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day 10 and processed as described for medium harvested
after 48 h.
Cell differentiation into mesodermal lineages
Cells were passaged (P4) to 48-well plates at a density of
~ 103 cells/well (9090 cells/cm2) and expanded in GM
without amphotericin B. At ~ 80% confluency, cells were
washed with sterile PBS and medium was changed to
chondrogenic differentiation medium (DMEM 4.5 g/L
glucose, without phenol red, supplemented with 1% (v/v)
GlutaMAX (Thermo Fischer Scientific, Waltham, MA,
USA), 1% (v/v) pyruvate (Thermo Fischer Scientific,
Waltham, MA, USA), 2% (v/v) FBS, 1% (v/v) insulin-
transferrin-selenium (ITS) (Thermo Fischer Scientific,
Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL
streptomycin, 10−7M dexamethasone (Sigma-Aldrich, St.
Louis, MO, USA), 50 μg/mL ascorbic acid (L-ascorbic acid
2-phosphate) (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/
mL TGF-β3 (recombinant human TGF-β3) (R&D Systems,
Inc., Minneapolis, MN, USA)) or osteogenic differentiation
medium (DMEM 1 g/L glucose, without phenol red, sup-
plemented with 1% (v/v) pyruvate (Thermo Fischer Scien-
tific, Waltham, MA, USA), 2% (v/v) FBS, 1% (v/v) ITS, 100
U/mL penicillin and 100 μg/mL streptomycin, 10−7M
dexamethasone, 50 μg/mL ascorbic acid (L-ascorbic acid 2-
phosphate), 10 μL/mL 1M β-glycerophosphate (β-glycero-
phosphate, disodium salt, pentahydrate) (Merck KGaA,
Darmstadt, Germany)). Differentiation medium was chan-
ged every 3 days for 21 days. Confirmation of chondrogenic
and osteogenic differentiation was performed by staining
for proteoglycans in the extracellular matrix using 0.1%
Safranin O, pH 4.6 (Merck KGaA, Darmstadt, Germany),
and calcified extracellular matrix deposits using 2% Alizarin
red staining, pH 4.2 (Sigma-Aldrich, St. Louis, MO, USA),
respectively.
Processing of the conditioned medium
Samples were thawed on ice and the proteins concen-
trated by use of a 3-kDa cut-off spin filter (Amicon
Ultra-4 Centrifugal filter unit) (Merck Millipore, Bur-
lington, MA, USA) followed by acetone precipitation (6×
acetone (v/v), 1 h, − 20 °C), which is the preferred prep-
aration method to be free of salts and other disturbing
agents [20]. The proteins were resuspended in 0.5 mL
0.5% sodium-deoxycylate (SDC) (Sigma-Aldrich, St.
Louis, MO, USA) in 50mM triethylammonium bicar-
bonate (TEAB) (Sigma-Aldrich, St. Louis, MO, USA)
and the total protein measured on a spectrophotometer
(DeNovix DS 11Fx) (Denovix, Wilmington, DE, USA) in
duplicates. A volume corresponding to 200 μg protein
was transferred to a 10-kDa cut-off spin filter (Amicon
Ultra-0.5 Centrifugal filter unit) (Merck Millipore,
Burlington, MA, USA) and 100 μL 0.5% SDC in 50mM
TEAB buffer was added. The proteins were reduced with
1:50 (v/v) 0.5M tris(2-carboxyethyl)phosphine (Thermo
Scientific, Waltham, MA, USA), alkylated with 1:10 (v/v)
0.5M chloroacetamide (Sigma-Aldrich, St. Louis, MO,
USA), and incubated 30min at 37 °C followed by centrifu-
gation for 15min at 14,000g. The buffer was exchanged
with 200 μL 0.5% SDC in 50mM TEAB followed by cen-
trifugation for 15min at 14,000g, and the flow-through
was discarded. Trypsin (1 μg/100 μg protein) was added,
and the proteins were digested overnight at 37 °C. The
digested samples were centrifuged 15min at 14,000g, the
filter washed by centrifugation with 100 μL 50mM TEAB
for 15min at 14,000g, and the flow-through used for fur-
ther processing.
The SDC was removed from the sample with phase
extraction by the use of 3:1 (v/v) ethyl acetate and acid-
ification by trifluoroacetic acid (pH < 2). After thorough
vortexing and centrifugation for 1 min at 14,000g, the
upper phase was discarded and the lower phase contain-
ing the digested proteins was dried down by vacuum
centrifugation. The samples were stored at − 20 °C.
LC-MS/MS analysis
Peptides were resuspended in resuspension buffer (2%
acetonitrile, 0.1% trifluoracetic acid (Thermo Fischer Sci-
entific, Waltham, MA, USA), 0.1% formic acid in MilliQ
water), and a volume corresponding to ~ 1 μg peptide
was analyzed by nanoLC-MS/MS (Thermo Scientific
Dionex Ultimate 3000 RSLC) coupled in line to a
Thermo Scientific Q Exactive HF mass spectrometer.
The peptide separation was accomplished using a pre-
column setup (Acclaim PepMap 100 C18 2 cm 100 μm
precolumn; 75 μm 75 cm main column) (Thermo Fischer
Scientific, Waltham, MA, USA) and a 60-min gradient
from 10% buffer B (99.9% acetonitrile) to 35% buffer B
and the buffer A being MilliQ water with 0.1% formic
acid. The mass spectrometer was set to acquire MS1
data from m/z 375–1500 at R = 60k and MS2 at R = 30k
allowing up to 20 precursor ions per MS1 scan.
Data analysis
Raw data was searched against the Equus caballus refer-
ence sequence database from Uniprot (UP000002281;
May 16, 2017; 22,698 proteins) using MaxQuant search
engines (MaxQuant v.1.6.0.1 and Perseus v.1.6.0.2). Only
proteins with at least two unique peptide sequences,
FDR < 1%, and identified in all technical replicates were
included. Label-free quantification (LFQ) was based on
total ion chromatogram normalization [21]. A difference
in intensity of the same protein in the different condi-
tions > 3× was considered significant. The R statistical
software version 3.3.2 (https://www.r-project.org) was
used for further analysis of the data. The heatmap was
generated in R by the use of R-packages “gplots”
(https://CRAN.R-project.org/package=gplots) and
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“RColorBrewer” (https://CRAN.R-project.org/package=
RColorBrewer). Protein descriptions and GO biological
processes found in Uniprot were used to group identified
proteins, and the online database STRING-DB vs 10.5 was
used to analyze interactions between clusters of proteins
[22]. The MS proteomics data have been deposited and
made publicly available to the ProteomeXchange Consor-
tium via the PRIDE partner repository with the dataset
identifier PXD016842 [23].
Results
Cellular morphology and differentiation into mesodermal
linages
Cells were plastic adherent and exhibited a fibroblast-like
morphology. Chondrogenic differentiated cells stained
positive for proteoglycans in the extracellular matrix and
osteogenic differentiated cells stained positive for calcified
extracellular matrix deposits on day 21 after induction of
differentiation.
Mass spectrometry analysis
A total of 706 proteins with at least 2 unique peptides
were identified with a 5% FDR on the protein level. A
scatter plot with log2-transformed LFQ values showed a
Pearson correlation of > 0.97 for triplicate analysis
(Supplementary 1 and 2).
Figure 2a shows a Venn diagram comparing the secre-
tomes from the four conditions after 48 h. A total of 309
proteins were common for all conditions. The proteins
identified in the secretomes from the IL1β-stimulated
conditions (EMIL48 and CMIL48) included a number of
proteins involved in the acute inflammatory response
such as IL1β, IL6, CXCL1, CXCL6, CCL7, semaphorin-
7A (SEMA7A), the acute phase proteins serum amyloid
A (SAA) and haptoglobin (HP), and the proteases
MMP8 and antileukoproteinase (SLPI). Proteins identi-
fied only in the secretome from EMIL48 included the
proteases MMP1 and MMP3 and the protease inhibitor
TIMP3, as well as CXCL8 and oncostatin M (OSM), in-
volved in the acute inflammatory response. Also, the
angiogenic proteins VCAM1, ICAM1, VEGFA, and
VEGFC were only identified in EMIL48. In the secre-
tome from chondrogenic differentiated cells, a number
of proteins involved in chondrogenesis were identified
such as cartilage oligomeric matrix protein (COMP),
stimulator of chondrogenesis 1 (SCRG1), xylotransferase
1 (XYLT1), and growth arrest-specific 6 (GAS6). Pro-
teins identified only in the secretome from CMIL48 in-
cluded vanin 1 (VNN1) and secreted phosphoprotein 1
(SPP1), also known as osteopontin, which both have a
role in inflammatory diseases.
The Venn diagram comparing the secretomes from
the four conditions after 10 h (Fig. 2b) showed a total of
297 proteins in common for all four conditions. Among
the 9 proteins identified in both conditions stimulated
with IL-1ß (EMIL10 and CMIL10) were the proteins
CXCL1, CXCL6, CCL7, MMP1, and MMP19. IL6 was
only identified in EMIL10. Secretogranin III (SCG3), in-
volved in platelet degranulation and angiogenesis, and
cartilage acidic protein 1 (CRTAC1), a protein upregu-
lated in synovial fluid from humans with OA, were also
only identified in the secretome from EMIL10. Proteins
identified only in the secretome from CMIL10 included
the inflammatory proteins SAA and IL11, gremlin
(GREM1) involved in regulation of chondrocyte and
osteoblast proliferation, and proteins involved in ECM
organization, e.g., laminin subunit gamma-2 (LAMC2),
cathepsin S (CTSS), and α-2-macroglobulin like 1
(A2ML1). In the secretome from chondrogenic differen-
tiated cells (CM10 and CMIL10), a number of proteins
involved in cartilage formation and bone mineralization
were identified such as COMP, SCRG1, epiphycan
(EPYC), osteomodulin (OMD), asporin (ASPN), and al-
kaline phosphatase (ALPL).
Fig. 2 Secretomes harvested after 48 h and 10 days from BM-MSCs with or without IL-1β stimulation. Venn diagram comparing the secretomes
harvested after a 48 h (48) and b 10 days (10) from equine bone marrow-derived mesenchymal stromal cells subjected to IL-1β stimulation (IL) for
5 days followed by 5 days without inflammation. At both time points, the secretome from naïve cells (EM) and chondrogenic differentiating cells
(CM) was assessed
Bundgaard et al. Stem Cell Research & Therapy          (2020) 11:187 Page 5 of 10
Figure 3 presents the majority of identified proteins
involved in either the inflammatory response, ECM
organization, or chondrogenesis in a heatmap based on
the difference in intensity between EM48/EMIL48,
CM48/CMIL48, EM10/EMIL10, and CM10/CMIL10 re-
spectively. With a focus on the proteins differing in in-
tensity between the different conditions after 48 h, it was
found that TGF-β1 was identified with a higher intensity
in the secretome from EM48IL compared to EM48. The
intensity of the protein interleukin 6 receptor beta unit
(IL6ST), important in the receptor system for various in-
flammatory proteins and also osteoblast differentiation, was
significantly higher in the secretome from inflammatory-
stimulated cells compared to non-stimulated.
Analysis of the intensity of proteins after 10 days
showed that amyloid-beta precursor protein (APP), pro-
lyl endopeptidase FAP (FAP), and integrin alpha-4
(ITGA4) involved in various processes including both
ECM organization and the inflammatory response were
identified in the secretome from naïve cells only after
stimulation with IL-1β, while they were identified in the
secretome from both CM10 and CMIL10, and only FAP
had a significantly higher intensity in the secretome
from CM10IL compared to CM10. Cartilage acidic pro-
tein 1 (CRTAC1) was only identified in EMIL10. The
enzyme (XYLT1) involved in cartilage ECM organization
was identified in both CM10 and CMIL10, but only in
the secretome from EMIL10.
The cell surface receptor CD44, which is a mesenchymal
stromal cell marker, but also a receptor that participates
in a wide variety of cellular functions including the inflam-
matory response and ECM organization, was identified
with a significantly higher intensity in the secretome from
EMIL compared to secretome from non-stimulated naïve
cells both after 48 h and 10 days. The intensity of CD44 in
the secretome from CM and CMIL did not differ signifi-
cantly at the two time points.
The proteins lumican and decorin expressed in cartil-
age were identified with the same intensity in the secre-
tome from chondrogenic differentiated cells after 48 h
and 10 days regardless of IL-1β stimulation. The inten-
sity for these two proteins was higher in the secretome
from non-stimulated naive cells compared to IL-1β-
stimulated cells after both 48 h and 10 days, but it was
not significant. Connective tissue growth factor (CTGF),
a protein involved in chondrogenesis, was observed in a
significantly higher intensity in IL-1β stimulated com-
pared to non-stimulated chondrogenic cells after 48 h,
but had the same intensity after 10 days. CTGF was also
expressed in EM and EMIL after both 48 h and 10 days,
but with no significant difference. The intensity for
procollagen-lysine,2-oxoglutarate 5 (PLOD) 1, PLOD 2,
PLOD 3, and cartilage associated protein (CRTAP), im-
portant proteins for collagen fibril formation, was in the
same range in the secretome from all chondrogenic dif-
ferentiated cells after 48 h and 10 days, and from EM48,
but had a tendency towards a lower intensity in the
secretome from EMIL10 compared to EM10. EFEMP1, a
negative regulator of chondrogenesis, was identified in a
higher concentration in the secretome for EMIL. The
concentration did not differ in chondrogenic differenti-
ating cells.
Discussion
In this study, BM-MSCs were subjected to inflammation
for 5 days followed by 5 days without inflammation.
Samples were harvested after 48 h of inflammation mim-
icking acute inflammation [24, 25], and again on day 10
to evaluate the cells’ recovery after the inflammatory in-
sult. At both time points, the modulatory effect of chon-
drogenic differentiation on the inflammatory response
was assessed.
The findings in this study indicate that naïve BM-MSCs
have a more extensive inflammatory response at 48 h to
stimulation with IL-1β compared to BM-MSCs undergo-
ing chondrogenic differentiation (EMIL48 and CMIL48).
This extensive inflammatory response decreased after
5 days without IL-1β (day 10), but a difference in compos-
ition of the secretome between naïve and chondrogenic
BM-MSC (EMIL10 and CMIL10) was still evident.
It is well known that IL-1β activates the nuclear
factor-kB (NF-kB) pathway, a proinflammatory signaling
pathway leading to release of a large array of cytokines
(e.g., IL1, IL6, CXCL8), chemokines (e.g., CXCL1,
CXCL10, IL18), adhesion molecules (e.g., ICAM1,
VCAM1, MMPs), and various other proteins involved in
inflammation [26]. The inflammatory proteins IL6,
CXCL1, CXCL6, CCL7, SEMA7A, SAA, and haptoglobin
were all identified in the secretome after 48 h from cells
stimulated with IL-1β. IL6 is known as a main down-
stream target of IL-1β via the NF-kB pathway [26], and
IL6 is one of the most important inflammatory cytokines
[27]. IL6 is a strong activator of the acute phase re-
sponse with expression of SAA and HP among others
[27]. The chemokines CXCL1 and CXCL6 are chemo-
tactic cytokines involved in various pathological pro-
cesses including inflammatory diseases, and it has been
shown that both CXCL1, CXCL6, and SEMA7A are in-
volved in the inflammatory response in joint-related dis-
eases such as rheumatoid arthritis [28, 29]. Also, IL-1β
was identified in the secretome from both EM48IL and
CM48IL, but it was not possible to distinguish between
IL-1β produced by BM-MSC and the recombinant
equine IL-1β used for stimulation. In a previous study,
the gene expression of IL-1β was upregulated in equine
BM-MSCs after 24 h conditioning with IL-1β [24], which
supports a positive feedback loop of IL-1β in equine
BM-MSCs.
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A number of proteins produced in response to NF-kB
pathway activation were identified only in the secretome
from EMIL48. CXCL8 and OSM are essential proinflam-
matory proteins similar to IL6. CXCL8 is released upon
NF-kB pathway activation and is especially chemoattract-
ant on neutrophils [30], and OSM in combination with
IL-1 has been shown to upregulate various inflammatory
and MMP genes [31]. CXCL8, OSM, and the proteases
MMP1 and MMP3 and the protease inhibitor TIMP3
were among the proteins involved in the acute inflamma-
tory response only identified in the secretome from
EMIL48. Proinflammatory cytokines such as IL1β and IL6
have been shown to activate the mitogen-activated protein
kinase and Janus kinase/signal transducers and activators
of transcription (JAK/STAT) pathway leading to increased
synthesis of MMP1 and MMP3 [32]. These proteases are
among the MMPs playing a critical role in the destruction
of articular cartilage in various joint diseases [32]. Upregu-
lation of MMP1, MMP3, and the protease inhibitor
TIMP3 in the secretome from EMIL48 suggests that naïve
BM-MSCs promote proteolytic activity in response to IL-
1β stimulation. The multifunctional cytokine TGF-β1 was
also among the proteins with a significant higher concen-
tration in the secretome from EMIL48 compared to
EM48. In OA, it has been found that TGF-β expression
increases in the early stages in an attempt to counteract
the catabolic effects of inflammatory cytokines such as IL-
1β or TNFα [33]. Also, the angiogenic proteins VCAM1,
ICAM1, VEGFA, and VEGFC were only identified in
EMIL48. The inflammatory response depends on migra-
tion of leukocytes, and VCAM1 and ICAM1 have been
shown to be essential in the process of leukocyte emigra-
tion to sites of inflammation [34], and it is known that the
angiogenic process on sites of inflammation is perpetuated
primarily by VEGF [35]. This indicates that naive
BM-MSCs stimulated with IL-1β also have angiogenic
properties. The cellular response for naïve BM-MSCs
to inflammatory stimulation is in line with the find-
ings in a study of the secretome from human BM-
MSCs stimulated with IL-1β, IL6, and TNFα. Here
they also found an increase of a broad range of pro-
teins related to inflammation, protease activity, and
angiogenesis [9]. Gene expression of proinflammatory
Fig. 3 Differences in the secretomes harvested after 48 h and 10
days from BM-MSCs with or without IL-1β stimulation. Heatmap
showing the difference in protein intensity in the secretomes
harvested after 48 h (48) and 10 days (10) from equine bone
marrow-derived mesenchymal stromal cells subjected to IL-1β
stimulation (IL) for 5 days followed by 5 days without inflammation.
At both time points, the secretome from naïve cells (EM) and
chondrogenic differentiating cells (CM) was assessed. The proteins
included are involved in either the inflammatory response,
extracellular matrix organization, or chondrogenesis. The data has
been log10 transformed
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molecules in equine BM-MSCs was also increased
after inflammatory conditioning for 12–72 h, and it
was demonstrated that the inflammatory response
profile was affected by the type of conditioning, con-
centration of the proinflammatory cytokines, and the
duration of the stimulation [24, 25, 36].
In a previous study, it was shown that IL-1β inhibited
chondrogenic differentiation of human BM-MSCs aspi-
rated from femurs of patients undergoing total hip re-
placement [37]. They did not include non-differentiating
cells, and cells were only analyzed after 28-day culture,
but the findings highlight the importance of further
studies on the effect of inflammation on MSC and devel-
oping strategies to prepare the MSCs for an inflamma-
tory in situ environment. In our study, the two proteins
VNN1 and SPP1 were identified in the secretome from
CMIL48. VNN1 has been studied in many different
inflammatory diseases showing that it has either a pro-
tective or a sensitizing role [38], but the role in joint dis-
eases has not been studied. For SPP1, also known as
osteopontin, it has been indicated that it causes a de-
crease of collagen 2 and COMP in chondrocytes from
osteoarthritis [39], but in OA progression, it plays an im-
portant role as a regulator [40], and it has been identi-
fied as a susceptibility gene for RA [41].
Taken together, these data propose that naïve BM-MSCs
have a more extensive inflammatory response, including
proteolytic and angiogenic activity, to stimulation with IL-
1β after 48 h (EMIL48) compared to BM-MSC undergoing
chondrogenic differentiation (CMIL48). This indicates that
chondrogenic differentiation or a chondrogenic environ-
ment has a protective mechanism to IL-1β stimulation.
After 10-day incubation, the proteins CXCL1, CXCL6,
and CCL7 were still identified in the secretome from
BM-MSC stimulated with IL-1β, as after 48-h incuba-
tion, but the essential inducer of the acute inflammatory
response, IL6, was only identified in the secretome from
EMIL10 and not CMIL10. This further supports that IL-
1β induces inflammation in BM-MSCs and that chon-
drogenic differentiation or a chondrogenic environment
works as a moderator to IL-1β stimulation and facilitates
a faster recovery after IL-1β stimulation. Also, the prote-
ases MMP1 and MMP19 were both identified in the
secretome from EMIL10 and CMIL10 indicating that
there was still some degradation activity [32]. The pro-
teins SAA and IL11 that both induce angiogenesis in RA
[42, 43] were identified in the secretome from CMIL10
only. This indicates that there still was some inflamma-
tory induced angiogenesis activity in this condition.
It has been demonstrated that the secretome from hu-
man BM-MSC can be used to describe the molecular
mechanism during chondrogenesis [8]. In this study, a
number of proteins related to cartilage were identified in
the secretome from BM-MSCs cultured in a chondrogenic
environment validating that the cells were undergoing
chondrogenesis. After 48 h, these proteins included COMP,
an important protein in cartilaginous ECM [44], SCRG1
[45], XYLT1 [46], and GAS6. After 10 days, these proteins
included COMP, SCRG1, EPYC [47], OMD [48], ASPN
[49], and ALPL [50]. The proteins lumican and decorin are
expressed in the cartilage [51] and have both been sug-
gested as chondrogenic markers [52, 53]. They were identi-
fied in all conditions, but the MS spectral intensity profiles
were markedly higher for these proteins in the chondro-
genic conditions compared to the naïve conditions.
The composition of the secretome was analyzed by
MS, and the raw data was searched against the Equus
caballus reference database from Uniprot. In accord-
ance with the guidelines from the Human Proteome
Organization (HUPO) [54], only proteins with at least
two unique peptide sequences were included in the
analyses of the secretomes. It should be noted that the
reference database does not yet cover the complete
equine genome. Moreover, a substantial part of the se-
quences in the reference database are derived from tran-
scripts, which cause redundancy in protein assignments
and fragment variants of the same sequence. To minimize
the impact of this fact on the results and further improve
the validity and quality of the study outcome, we only in-
cluded proteins identified in all three replicates in the final
analyses of the secretomes.
In conclusion, this study showed that naïve BM-MSCs
had a more extensive inflammatory response at 48 h to
stimulation with IL-1β compared to BM-MSCs undergo-
ing chondrogenic differentiation. This extensive inflam-
matory response decreased after 5-day recovery time
without IL-1β (day 10), but a difference in composition
of the secretome between naïve and chondrogenic BM-
MSCs remained evident. This study is descriptive and
shows the effect of differentiation status on sensitivity to
inflammation in BM-MSCs. The work in this study is
important when considering BM-MSC therapy, because
the findings indicate that BM-MSCs will be strongly in-
fluenced by an inflammatory environment present in the
host compartment upon injection even later after the
inflammation has subsided and that chondrogenic differ-
entiation or a chondrogenic environment may have a
protective mechanism to IL-1β stimulation. Further
studies are needed to evaluate if this effect is transferable
to other MSC types and to establish the functional and
mechanistic consequences for use of MSC in therapy.
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spectrometry analysis of the secretomes harvested after 1) 48 h (48) and
2) 10 days (10) from equine bone marrow-derived mesenchymal stromal
cells subjected to IL-1β stimulation (IL) for five days followed by five days
without inflammation. At both time points, the secretome from naïve
cells (EM) and chondrogenic differentiating cells (CM) was assessed.
Additional file 2: Supplementary 3. Table with data used for the
heatmap.
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